The Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) by Melo-Gomes, Jose Antonio et al.
Vol.:(0123456789) 
Rheumatology International (2018) 38 (Suppl 1):S323–S329 
https://doi.org/10.1007/s00296-018-3967-7
VALIDATION STUDIES
The Portuguese version of the Juvenile Arthritis Multidimensional 
Assessment Report (JAMAR)
Jose Antonio Melo‑Gomes1 · Filipa Oliveira‑Ramos2,3 · Alessandro Consolaro4,5 · Francesca Bovis4 · 
Nicolino Ruperto4 · For the Paediatric Rheumatology International Trials Organisation (PRINTO)
Received: 22 December 2017 / Accepted: 11 January 2018
© The Author(s) 2018. This article is an open access publication
Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Portuguese language. 
The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, and construct validity (convergent and discriminant validity). 
A total of 80 JIA patients (6.3% systemic, 68.8% oligoarticular, 3.7% RF negative polyarthritis, 21.2% other categories) 
and 30 healthy children were enrolled. The JAMAR components discriminated well healthy subjects from JIA patients. 
All JAMAR components revealed good psychometric performances. Notably, there was no significant difference between 
healthy subjects and their affected peers in school-related items. In conclusion, the Portuguese version of the JAMAR is a 
valid tool for the assessment of children with JIA and is suitable for use both in routine clinical practice and clinical research.
Keywords Juvenile idiopathic arthritis · Disease status · Functional ability · Health-related quality of life · JAMAR
Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Portuguese parent, child/adult version of 
the Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient 
reported outcomes in JIA, including overall well-being, 
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functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Portuguese language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] enrolled from January 2013 to 
March 2017. Children were recruited after Ethics Committee 
approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task 
is scored as follows: 0 = without difficulty, 1 = with 
some difficulty, 2 = with much difficulty, 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL); PF-hand 
and wrist (PF -HW) and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10];
 2. rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11];
 3. assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. assessment of morning stiffness (present/absent);
 5. assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. rating of the level of disease activity on a 21-circle 
VAS;
 7. rating of disease status at the time of the visit (categori-
cal scale);
 8. rating of disease course from previous visit (categori-
cal scale);
 9. checklist of the medications the patient is taking (list 
of choices);
 10. checklist of side effects of medications;
 11. report of difficulties with medication administration 
(list of items);
 12. report of school/university/work problems caused by 
the disease (list of items);
 13. assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14];
 14. rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. a question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of 10 JIA parents 
and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Lik-
ert assumption [mean and standard deviation (SD) equiva-
lence]; the second Likert assumption or equal items–scale 
correlations (Pearson r: all items within a scale should con-
tribute equally to the total score); third Likert assumption 
(item internal consistency or linearity for which each item 
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of a scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes 
of the scales, respectively); internal consistency, measured 
by the Cronbach’s alpha, interscale correlation (the corre-
lation between two scales should be lower than their reli-
ability coefficients, as measured by Cronbach’s alpha); and 
construct validity in its two components: the convergent 
or external validity which examines the correlation of the 
JAMAR subscales with the six JIA core set variables, with 
the addition of the parent assessment of disease activity 
and pain by the Spearman’s correlation coefficients (r) [17] 
and the discriminant validity, which assesses whether the 
JAMAR discriminates between the different JIA categories 
and healthy children [18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Portuguese parent and patient versions of 
the JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Portuguese JAMAR was fully cross-culturally adapted 
from the standard English version with three forward and 
two backward translations with a concordance for 122/123 
(99.2%) translations lines for the parent version and 118/120 
(98.3%) lines for the child version. All the 123 lines in 
the parent version of the JAMAR were understood by at 
least 80% of the 10 parents tested (median = 100%; range: 
100–100%). All the 120 lines in the patient version of the 
JAMAR were understood by at least 80% of the children 
(median = 100%; range: 100–100%).
Both versions of the JAMAR were unmodified after the 
probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 80 JIA patients were enrolled at the paediatric 
rheumatology centres of the Portuguese Institute of Rheu-
matology and Hospital Santa Maria in Lisbon. At the Study 
Unit, it has been possible to enrol only 30 healthy children 
(total 110 subjects).
In the 80 JIA subjects, the JIA categories were 6.3% with 
systemic arthritis, 68.8% with oligoarthritis, 3.7% with RF 
negative polyarthritis, 3.7% with RF positive polyarthritis, 
13.8% with enthesitis-related arthritis and 3.7% with undif-
ferentiated arthritis (Table 1). Notably, none of the enrolled 
JIA patients is affected with psoriatic arthritis.
A total of 103/110 (93.6%) subjects had the parent ver-
sion of the JAMAR completed by a parent (74 from parents 
of JIA patients and 29 from parents of healthy children). 
The JAMAR was completed by 79/103 (76.7%) mothers and 
24/103 (23.3%) fathers. The child version of the JAMAR 
was completed by 109/110 (99.1%) children age 7.1 years 
or older.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well 
between healthy subjects and JIA patients. Notably, there 
was no significant difference between healthy subjects and 
their affected peers in school-related items.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The fol-
lowing “Results” section refers mainly to the parent’s ver-
sion findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did 
not allow to skip answers and input of null values.
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL.
A reduced number of response choices were used for 
all the different HRQoL items except for items 1, 3 and 4, 
whereas a reduced number of response choices were used 
for PF items 1, 7 and 8.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items 
(data not shown).
The median number of items marked as not applicable 
was 0% (0–0%) for the PF and 1% (0–1%) for the HRQoL 
items.
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Table 1  Descriptive statistics (medians, 1st 3rd quartiles or absolute frequencies and %) for the 80 JIA patients
Data related to the JAMAR refers to the 74 JIA patients and to the 29 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refers to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001
Systemic Oligoarthritis RF− Poly-
arthritis
RF + Poly-
arthritis
Enthesitis-
related arthritis
Undifferentiated 
arthritis
All JIA patients Healthy
N = 5 N = 55 N = 3 N = 3 N = 11 N = 3 N = 80 N = 30
Female 4 (80%) 43 (78.2%) 2 (66.7%) 3 (100%) 2 (18.2%) 3 (100%) 57 (71.3%)* 14 (46.7%)*
Age at visit 17.8 (17.1–
30.5)
13.6 (9.9–16) 14.7 (12.4–
25.8)
18.4 (14.1–
24.3)
17.4 (12.4–
22.5)
22.9 (10.2–
23.9)
14.5 (11.1–
17.6)*
11.8 (9.9–
13.2)*
Age at onset 4.3 (4–6) 3 (2-7.1) 6.3 (3.5–11.8) 10.1 (8.6–11.2) 9.8 (8.1–11.6) 9.5 (7.9–14.6) 5.2 (2.3-9)**
Disease duration 14 (12.2–26.5) 8.7 (4.1–12.7) 8.4 (0.6–22.3) 8.3 (2.9–15.8) 7 (4.1–12) 8.3 (2.3–14.3) 8.8 (4.2–13.1)
ESR 9 (6–25) 9 (6–17) 3 (1–52) 13 (12–25) 9 (6–23) 14 (2–18) 9 (6–18)
MD VAS 1 (0–1) 0 (0–0) 0.5 (0–1) 0 (0–2) 0 (0–1) 1 (1–2) 0 (0–1)
No. swollen joints 0 (0–0) 0 (0–0) 0 (0–23) 0 (0–0) 0 (0–0) 0 (0–2) 0 (0–0)
No. joints with 
pain
0 (0–1) 0 (0–0) 0 (0–54) 0 (0–6) 1 (0–2) 2 (1–2) 0 (0–1)*
No. joints with 
LOM
2 (0–2) 0 (0–2) 20 (0–36) 0 (0–0) 0 (0–2) 0 (0–1) 0 (0–2)
No. active joints 0 (0–0) 0 (0–0) 0 (0–35) 0 (0–0) 0 (0–0) 0 (0–2) 0 (0–0)
Active systemic 
features
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
ANA status 0 (0%) 34 (61.8%) 1 (33.3%) 0 (0%) 0 (0%) 1 (33.3%) 36 (45%)**
Uveitis 0 (0%) 11 (20%) 0 (0%) 0 (0%) 0 (0%) 1 (33.3%) 12 (15%)
PF Total Score 0 (0–2) 0 (0–3) 12 (0–24) 3 (1–5) 1 (0–1) 3 (0–6) 0 (0–3) 0 (0–0)**
Pain VAS 0 (0–0) 0 (0–0) 0 (0–0) (–) 1 (0–2) 3 (1–4) 0 (0–1)* 0 (0–0)*
Disease Activity 
VAS
0.5 (0–1) 0 (0–1) 0 (0–0) 2 (2–2) 1 (0–1) 3 (1–8) 0 (0–1)
Well-being VAS 0 (0–0) 0 (0–2) 3.5 (0–7) 3 (3–3) 1 (0.5-2) 1 (0–4) 0 (0–2)
HRQoL-PhH 0 (0–1) 1 (0–3) 7 (0–14) 4 (4–4) 2 (1–4) 1 (1–5) 1 (0–3) 0 (0–0)#
HRQoL-PsH 0 (0–1) 0 (0–2) 4.5 (0–9) 0.5 (0–1) 1 (0–2) 2 (1–4) 0.5 (0–2) 0 (0–0)**
HRQoL Total 
Score
1 (0–1) 2 (0–5) 11.5 (0–23) 5 (4–6) 3.5 (1–5) 5 (3–7) 3 (0–5) 0 (0–0)#
Pain/swell. in > 1 
joint
2/3(66.7%) 18/54 (33.3%) 1/2 (50%) 2/2 (100%) 6/10 (60%) 2 (66.7%) 31/74 (41.9%) 0 (0%)#
Morning stiff-
ness > 15 min
2/3 (66.7%) 2/54 (3.7%) 1/2 (50%) 0 (0%) 2/10 (20%) 1 (33.3%) 8/74 (10.8%)* 8/74 (71.8%)*
Subjective remis-
sion
1/3 (33.3%) 18/54 (33.3%) 1/2 (50%) 1/2 (50%) 6/10 (60%) 2 (66.7%) 29/74 (39.2%)
In treatment 2/3 (66.7%) 42/54 (77.8%) 2/2 (100%) 2/2 (100%) 10/10 (100%) 3/3 (100%) 61/74 (82.4%)
Reporting side 
effects
0 (0%) 7/42 (16.7%) 1/2 (50%) 0 (0%) 2/10 (20%) 2/3 (66.7%) 12/61 (19.7%)
Taking medication 
regularly
2/2 (100%) 39/42 (92.9%) 2/2 (100%) 2/2 (100%) 9/10 (90%) 3/3 (100%) 57/61 (93.4%)
With problems 
attending school
0 (0%) 1/37 (2.7%) 1/2 (50%) 0 (0%) 0 (0%) 2/43 (4.7%) 0 (0%)
Satisfied with dis-
ease outcome
3/3 (100%) 47/54 (87%) 1/2 (50%) 2/2 (100%) 10/10 (100%) 3/3 (100%) 66/74 (89.2%)
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Floor and ceiling effect
The median floor effect was 89.2% (85.1–95.9%) for the 
PF items, 73.0% (55.4–75.7%) for the HRQoL-PhH items, 
and 74.3% (70.3–75.7%) for the HRQoL-PsH items. The 
median ceiling effect was 0% (0–0%) for the PF items, 
2.7% (1.4–2.7%) for the HRQoL-PhH items, and 1.4% 
(1.4–2.7%) for the HRQoL-PsH items. The median floor 
effect was 51.3% for the pain VAS, 44.6% for the disease 
activity VAS and 41.9% for the well-being VAS. The 
median ceiling effect was 0% for the pain VAS, 0% for 
the disease activity VAS and 0% for the well-being VAS.
Equal items–scale correlations (second Likert 
assumption)
Pearson items–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 93% of the 
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 74/103 Child N = 79/109
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 89.2% 91.1%
 HRQoL-PhH 73.0% 73.4%
 HRQoL-PsH 74.3% 75.9%
 Pain VAS 51.3% 45.6%
 Disease activity VAS 44.6% 45.6%
 Well-being VAS 41.9% 41.8%
Ceiling effect, median
 PF 0.0% 0.0%
 HRQoL-PhH 2.7% 1.3%
 HRQoL-PsH 1.4% 0.0%
 Pain VAS 0.0% 1.3%
 Disease activity VAS 0.0% 0.0%
 Well-being VAS 0.0% 0.0%
Items with equivalent item–scale correlation 93% for PF, 90% for HRQoL 87% for PF, 100% for HRQoL
Items with items–scale correlation ≥ 0.4 73% for PF, 100% for HRQoL 93% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.90 0.87
 PF-HW 0.87 0.85
 PF-US 0.42 0.80
 HRQoL-PhH 0.88 0.86
 HRQoL-PsH 0.84 0.76
Items with item–scale correlation lower than the Cronbach’s alpha 93% for PF, 100% for HRQoL 80% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.95 1.00
 HRQoL-PhH 0.08 0.00
 HRQoL-PsH 0.65 0.49
Spearman correlation with JIA core set variables, median
 PF 0.3 0.3
 HRQoL-PhH 0.3 0.5
 HRQoL-PsH 0.2 0.2
 Pain VAS 0.2 0.4
 Disease activity VAS 0.4 0.5
 Well-being VAS 0.3 0.5
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PF items, with the exception of PF item 15, and for 90% of 
the HRQoL items, with the exception of HRQoL item 1.
Items internal consistency (third Likert assumption)
Pearson items–scale correlations were ≥ 0.4 for 73% of items 
of the PF (except for PF items 11, 12, 14 and 15) and 100% 
of items of the HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.90 for PF-LL, 0.87 for PF-HW, 0.42 
for PF-US. Cronbach’s alpha was 0.88 for HRQoL-PhH and 
0.84 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha for 
all the items (except for PF item 13).
Test–retest reliability
Reliability was assessed in 10 JIA patients, by re-admin-
istering both versions (parent and child) of the JAMAR 
after a median of 9 days (7–11 days). The intraclass cor-
relation coefficients (ICC) for the PF total score showed an 
almost perfect reproducibility (ICC = 0.95). The ICC for the 
HRQoL PhH showed a poor reproducibility (ICC = 0.08) 
while the ICC for the HRQoL-PsH showed a substantial 
reproducibility (ICC = 0.65).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.2 to 0.4 
(median = 0.3). The PF total score best correlation was 
observed with the parent assessment of disease activity 
(r = 0.6, p < 0.001). For the HRQoL, the median correlation 
of the PhH with the JIA core set of outcome variables ranged 
from 0.3 to 0.7 (median = 0.3), whereas for the PsH ranged 
from − 0.01 to 0.4 (median = 0.2). The PhH and the PsH 
showed the best correlation with the parent global assess-
ment of well-being (r = 0.8, p < 0.001 and r = 0.5, p < 0.001, 
respectively). The median correlations between the pain 
VAS, the well-being VAS, and the disease activity VAS 
and the physician-centred and laboratory measures were 0.2 
(0.2–0.4), 0.4 (0.3–0.4), 0.3 (0.2–0.6), respectively.
Discussion
In this study, the Portuguese version of the JAMAR was 
cross-culturally adapted from the original standard English 
version with three forward and two backward translations. 
According to the results of the validation analysis, the Por-
tuguese parent and patient versions of the JAMAR possess 
satisfactory psychometric properties. The disease-spe-
cific components of the questionnaire discriminated well 
between patients with JIA and healthy controls. However, 
we have to acknowledge that the Portuguese version of the 
JAMAR was validate only in 30 healthy children. Notably, 
there was no significant difference between the healthy 
subjects and their affected peers in the school-related prob-
lems. These findings could indicate that children with JIA 
adapt well to the consequences of JIA, and have school 
performances comparable to those of their healthy peers.
Psychometric performances were good for all domains 
of the JAMAR with few exceptions: four PF items (stretch 
arms, put hands behind neck, bend head back and look 
at the ceiling and bite a sandwich or an apple) showed 
a lower item’s internal consistency. However, the overall 
internal consistency was good for all the domains with the 
exception of the PF-US Cronbach’s alpha.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from weak to moderate.
The statistical performances of the child version of the 
JAMAR are very similar, even slightly better, to those 
obtained by the parent version, which suggests that chil-
dren are reliable reporters of their disease and health 
status.
The JAMAR is aimed to evaluate the side effects of 
medications and school attendance, which are other dimen-
sions of daily life that were not previously considered by 
other HRQoL tools. This may provide useful information 
for intervention and follow-up in health care.
In conclusion, the Portuguese version of the JAMAR 
was found to have satisfactory psychometric properties 
and it is, thus, a reliable and valid tool for the multidimen-
sional assessment of children with JIA.
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